drugset / Trial / NCT04584580
D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia
RandomizedParallel-groupSingle-blindSupportive care
Summary
evaluation of the efficacy and safety of D-dimer adjusted heparin versus therapeutic dose heparin in patients with COVID-19 Pneumonia.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2020-10-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 60 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 120 mg | Subcutaneous |